Caldera, Evommune sign China licensing deals for autoimmune drugs
The biopharma industry was already on pace for one China deal per week for the entire year. Now, another two biotechs have snagged assets from the world's busiest shopping mall for new ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.